Holistic Planning LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Holistic Planning LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.2% during the fourth quarter, Holdings Channel reports. The firm owned 51,573 shares of the biopharmaceutical company’s stock after buying an additional 5,209 shares during the quarter. Holistic Planning LLC’s holdings in Pfizer were worth $1,368,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the fourth quarter worth approximately $26,000. Gladius Capital Management LP boosted its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP bought a new stake in Pfizer during the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer during the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management raised its position in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $26.51 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock’s 50 day simple moving average is $26.27 and its two-hundred day simple moving average is $27.85.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.